Overall Survival Rate of Vietnamese Patients with Colorectal Cancer: A Hospital-Based Cohort Study in the Central Region of Vietnam

Duong Dinh Le¹,², Thang Van Vo²,³, Pongdech Sarakarn¹,⁴*

Abstract

Background: This study investigated the overall survival (OS) at 1-year, 3-years, and 5-years after colorectal cancer (CRC) diagnosis and examined the prognostic factors of mortality among patients with CRC in Vietnam’s central region. Methods: This ambidirectional cohort study included patients newly diagnosed with CRC at a tertiary hospital in Vietnam’s central region between 2013 and 2019. Survival duration was calculated from the surgery date or the first day of CRC-specific treatment until the date of death or the study’s end date, July 31, 2020. Kaplan-Meier methods and log-rank test were used to estimate and compare the OS between the subgroups, respectively. The Cox proportional-hazards (PH) regression analysis was applied to estimate the magnitude of the effects between prognostic factors and outcome. Results: The median follow-up was 24 months (interquartile range: 13–43 months). The OS rate dropped significantly to 84.7%, 56.19%, and 45.01% at 1-year, 3-years, and 5-years after diagnosis, respectively. The median OS was 48.59 months (39.34 –57.93 months) for the rectum and colon cases. In the multivariate analysis, a higher mortality risk was observed in patients with an advanced-stage CRC (HRadj, 3.04; 95% confidence interval [CI], 1.79–5.18), who were underweight (<18.5 kg/m²; HRadj, 1.65; 95%CI, 1.03–2.65), and had elevated preoperative carcinoembryonic antigen (CEA) level (>5.0 ng/mL; HRadj, 1.63; 95%CI, 1.03–2.59). Additionally, younger patients (<50 years) had a poorer OS than the middle-aged group (60–69 years). Conclusion: Our findings indicate that <50% of Vietnamese patients with CRC survive until 5-years after diagnosis. Several individual factors that contribute to the poor OS of patients with CRC, including young age, underweight, and elevated preoperative CEA level, should be evaluated and managed. Early diagnoses through active routine examination of or screening programs for high-risk groups should be prioritized.

Keywords: Colorectal cancer- overall survival- ambidirectional cohort- Vietnamese

Introduction

The burden of colorectal cancer (CRC) has become an important public health issue, which is predicted to increase by 60%, with 2.2 million incident cases and 1.1 deaths by 2030 (Arnold et al., 2017). According to the 2020 GLOBOCAN report, CRC is the second leading cause of cancer-related deaths based on cancer sites worldwide, which is estimated at 9.2% (Ferlay et al., 2020). Although both CRC incidence and mortality are declining in many developed countries, the trend has increased in several Asian countries (Arnold et al., 2017; Wild et al., 2020). Vietnam is a lower- to middle-income country (United, 2020) and is experiencing aging population trends and socioeconomic changes, which are considered the most notable CRC transition markers (Arnold et al., 2017; Hoang et al., 2019). The CRC burden is predicted to double in both incidence and mortality cases in the next two decades in Vietnam (Ferlay et al., 2020).

The survival rate of cancer patients is an essential indicator that reflects the effectiveness of cancer-specific treatment as well as preventive and cancer control programs (Li et al., 2019). In Asian countries, the overall survival (OS) rate of patients with CRC has not improved significantly in the past decades, with the 5-year OS unchanged at approximately 60% (Moghimi-Dehkordi and Safaee, 2012). The 5-year survival rate ranges from 36.87% in Thailand (Phimha et al., 2019) to 73.0% in Japan (Tamakoshi et al., 2017). Nevertheless, the national cancer control program has had limited effects in responding to the demands, particularly for screening programs and cancer-specific treatments (Tran et al., 2016;
Hoang et al., 2019; Pham et al., 2019). Many factors contribute to the limitation of cancer epidemiology and survival data, including the lack of surveillance data and the poor quality of cancer survival statistics (Rao et al., 2010; Shin et al., 2012; Hong et al., 2018). To date, the survival rate of CRC has been almost underestimated in Vietnam, and our work is expected to contribute novel knowledge of CRC survival scientific evidence. This study investigated the OS at 1-year, 3-years, and 5-years after diagnosis of CRC and examined the prognostic factors of mortality among Vietnamese patients with CRC in the central region of Vietnam.

**Materials and Methods**

**Study design**

This was an ambidirectional cohort study. The initial phase was a retrospective study using a hospital-based cohort from 2013 to 2019. The next phase was a prospective study of the cohort, wherein the identified CRC cases were followed up until the date of death or the study’s end date, July 31, 2020. Survival duration was calculated from the surgery date or the first day of CRC-specific treatment until the date of death or the study’s end date. The vital event status of CRC cases was confirmed from the local community health center where the patients were mostly managed through the national noncommunicable disease program.

**Setting**

This research was implemented in Hue Central Hospital (HCH), a tertiary hospital, established as the highest-level referral hospital for 14 provinces in the central region of Vietnam. The oncology center of HCH is responsible for providing cancer-specific treatment therapies, training, and medical technology implementation of other medical facilities in this area (Hue Central Hospital, 2020). HCH is located in Thu Thien Hué province in the North Central Coast region with a reported population of 1.13 million people in 2019 (General Statistics Office of Vietnam, 2020).

**Participants**

In the beginning, participants with newly diagnosed CRC were selected based on a hospital cohort from January 1, 2013 to December 31, 2019. A total of 639 residential cases were initially diagnosed at baseline and evaluated using the patients’ medical records. In the initial screening, 28 cases were excluded because of other concurrent malignant diseases at enrollment, they were prisoners, or were aged <18 years. Then, 611 confirmed cases were followed up until the date of death or the study’s end date. In our study, 12.2% of cases were withdrawn during the survival analysis, including loss to follow-up (65), emigration (4), and missing data on the exact date of death (6). The eligible participants are shown in Figure 1.

**Measurements**

The patients’ medical record was the primary source of data to collect their baseline characteristics, such as age and sex; clinical characteristics, such as tumor sites; height and weight; preoperative serum carcinoembryonic antigen (CEA) level; and comorbidities, including hypertension, diabetes, and cardiovascular diseases. In this study, CRC staging was classified using the American Joint Committee on Cancer TNM system, seventh edition (2010) (Stephen et al., 2010), which is based on the characteristics of the tumor (T), nodes (N), and metastasis (M). Body mass index (BMI) was calculated based on the patients’ height and weight at the first hospital admission and using the Asian-Pacific classification criteria for BMI grouping (World Health Organization–Regional Office for the Western Pacific, 2000).

The patients’ status was confirmed by the healthcare staff of the local community health center at their residence. In the survival analysis, the outcome was classified into event data as a death case and censored data as alive at the end of the study.

**Statistical analysis**

CRC patients’ demographic and clinical characteristics are presented as mean, standard deviation or median, and interquartile range (IQR) for continuous variables and number and percentage for categorical variables. The Kaplan-Meier estimate was used to depict the OS at 1-, 3-, and 5-year intervals after CRC diagnosis. The median OS with 95% confidence interval (CI) was used to present the survival duration, and the log-rank test was used to compare the OS between subgroups. The Cox proportional-hazards (PH) regression analysis was applied to estimate the magnitude of the effects between prognostic factors and outcome. Only the cases with complete information were selected for the multivariate analysis. The PH assumption was tested using the Schoenfeld residual test. P-values < 0.05 were considered statistically significant.

**Results**

**Baseline characteristics of patients with colorectal cancer**

Table 1 presents the participants’ baseline characteristics. The median age was 64 years (IQR: 52–76 years). There was an almost equal percentage between subgroups with respect to several factors: tumor sites, residence, and preoperative CEA level. The median preoperative CEA level was 5.15 ng/mL (IQR: 2.77–13.10). Comorbidities were concurrently observed in 35.63% of patients. Half of the patients had a normal weight, and nearly one-fourth of patients were underweight at enrollment. The median BMI was 20.46 kg/m², and the IQR was 18.37 to 22.43 kg/m². Surgical resection was the most CRC-specific treatment modality, accounting for 85.07%, whereas chemotherapy and radiotherapy were slightly over 50% and 20%, respectively. Among the available TNM stage classifications, advanced stage (III + IV) was observed in 34.33% of cases.

**Overall survival rate and median survival duration**

Table 2 shows the OS according to the time of diagnosis and tumor location. The median follow-up time was 24 months, with an IQR of 13 to 43 months. The OS
Table 1. Baseline Characteristics of Colorectal Cancer Patients

| Characteristics                  | Number | Percentage (%) |
|----------------------------------|--------|----------------|
| **Age groups (years)**           |        |                |
| < 50                             | 112    | 20.9           |
| 50 - 59                          | 103    | 19.22          |
| 60 - 69                          | 124    | 23.13          |
| 70 - 79                          | 109    | 20.34          |
| ≥80                              | 88     | 16.42          |
| **Gender**                       |        |                |
| Male                             | 295    | 55.04          |
| Female                           | 241    | 44.96          |
| **Residence**                    |        |                |
| Urban                            | 239    | 44.59          |
| Rural/ mountainous               | 297    | 55.41          |
| **Comorbidities**                |        |                |
| Hypertension                     | 153    | 28.54          |
| Diabetes                         | 60     | 11.19          |
| Cardiovascular diseases          | 41     | 7.65           |
| **BMI groups**                   |        |                |
| Underweight (<18.5 kg/m²)        | 131    | 24.44          |
| Normal (18.5–<23.0 kg/m²)        | 266    | 49.63          |
| Overweight (23.0–<25.0 kg/m²)    | 52     | 9.70           |
| Obesity (≥25 kg/m²)              | 41     | 7.65           |
| Unknown                          | 46     | 8.58           |
| **Tumor sites**                  |        |                |
| Colon                            | 278    | 51.87          |
| Rectum                           | 258    | 48.13          |
| **Disease stages**               |        |                |
| Stage I                          | 32     | 5.97           |
| Stage II                         | 111    | 20.71          |
| Stage III                        | 114    | 21.27          |
| Stage IV                         | 70     | 13.06          |
| Unknown stage                    | 209    | 38.99          |
| **Preoperative CEA level**       |        |                |
| Non elevated (<5ng/ml)           | 197    | 36.75          |
| Elevated (>5 ng/ml)              | 207    | 38.62          |
| Unknown                          | 132    | 24.63          |
| **Treatment modalities**         |        |                |
| SR only                          | 191    | 35.63          |
| SR + CT or RT                    | 195    | 36.38          |
| SR + CT + RT                     | 70     | 13.06          |
| CT/ RT without SR                | 36     | 6.72           |
| Not at all                       | 44     | 8.21           |

IQR, interquartile range; BMI, body mass index; CEA, Preoperative serum carcino-embryonic antigen; SR, surgical resection; CT, chemotherapy; RT, radiotherapy.

rate dropped significantly from 84.7% at 1 year to 45.01% at 5 years after diagnosis, and no significant difference was observed between the colon and rectal cancer cases. The median survival duration was 48.59 months for overall CRC, ranging from 39.34 to 57.93 months for colon and rectal cancers, respectively.

**Prognostics factors of overall survival in patients with colorectal cancer**

Table 3 shows the bivariate analysis of prognostic factors and the mortality rate of CRC cases. The OS was significantly different between age groups, disease stages, BMI groups, preoperative CEA levels, and treatment modalities. Nevertheless, sex, comorbidities, tumor sites, and residence had no statistically significant differences in OS.

Table 4 provides the multivariate analysis using the Cox PH regression analysis in a sample of 232 cases. Overall, age group, disease stage, BMI group, and preoperative CEA level were significantly associated with the OS of patients with CRC after adjusting for sex, comorbidities, and treatment modalities. Patients with advanced stage cancers had 3.04 times (HRadj: 3.04; 95%CI: 1.79–5.18) higher risk of mortality rate than those with early stage cancers. Middle-age groups (aged 60–69 years) were found to have a lower risk of death (HRadj: 0.47; 95%CI: 0.24–0.91) than the youngest age group (aged <50 years). In addition, CRC patients who were underweight (BMI <18.5 kg/m²) and had an elevated preoperative CEA level had a higher mortality risk at 1.65 and 1.63 times, respectively.

**Discussion**

Worldwide, the incidence of CRC continues to rise (Rawla et al., 2019), and the trend patterns of the disease correlate with the present human development levels, which may reflect the adoption of more Western lifestyles (Arnold et al., 2017). In 2020, more than one in two new CRC cases occurred in Asian countries (Ferlay et al., 2020). In this study, we focused on the OS rate based on the limited quality of mortality data; in particular, the cause of death in our nation (Hong et al., 2018; Pham et al., 2019).

The results of this study indicated that a reduction in the OS rate was apparent in Vietnamese patients with CRC. The OS declined significantly by approximately 40% from 84.7% at 1 year to 45.01% at 5 years after diagnosis. In our samples, the 5-year OS of colon cancer patients was 49.6% compared to 38.91% of rectal cancer patients, and no significant difference was found between the tumor sites (Table 2). Survival rates were studied previously (Coleman et al., 2011), with the 5-year survival rate at 16% in Ghana (Agyemang-Yeoah et al., 2018), 44% in Spain, 43.8% in Martinique (France) (Joachim et al., 2019), 63.5% in Brazil (Aguia et al., 2020), and 66.6% in the United States (Siegel et al., 2017). This variation was observed within a region, that is, the 5-year survival rate in Eastern Mediterranean countries was 57.26% (50.43%–64.10%), which varied from 29.5% in Libya to 95% in Lebanon (Nikbakht et al., 2020). We found that the 5-year OS of Vietnamese patients with CRC was approximately 60% lower than those in Asian countries (Moghimi-Dehkordi and Saafaei, 2012). Our findings are equivalent to those of neighboring countries, such as Thailand (Phimha et al., 2019; Kitttongsiri et al., 2020), Malaysia (Magaji et al., 2017), and Brunei (Leong et al., 2017). The results of this study indicated that a reduction in the OS rate was apparent in Vietnamese patients with CRC. The OS declined significantly by approximately 40% from 84.7% at 1 year to 45.01% at 5 years after diagnosis. In our samples, the 5-year OS of colon cancer patients was 49.6% compared to 38.91% of rectal cancer patients, and no significant difference was found between the tumor sites (Table 2). Survival rates were studied previously (Coleman et al., 2011), with the 5-year survival rate at 16% in Ghana (Agyemang-Yebosa et al., 2018), 44% in Spain, 43.8% in Martinique (France) (Joachim et al., 2019), 63.5% in Brazil (Aguiar et al., 2020), and 66.6% in the United States (Siegel et al., 2017). This variation was observed within a region, that is, the 5-year survival rate in Eastern Mediterranean countries was 57.26% (50.43%–64.10%), which varied from 29.5% in Libya to 95% in Lebanon (Nikbakht et al., 2020). We found that the 5-year OS of Vietnamese patients with CRC was approximately 60% lower than those in Asian countries (Moghimi-Dehkordi and Saafaei, 2012). Our findings are equivalent to those of neighboring countries, such as Thailand (Phimha et al., 2019; Kitttongsiri et al., 2020), Malaysia (Magaji et al., 2017), and Brunei (Leong et
## Table 2. Overall Survival Rate and Median Survival duration of CRC Patients

| Tumor location | Overall survival rate, % (95%CIs) | Median survival duration (95%CIs) |
|----------------|-----------------------------------|----------------------------------|
|                | 1-year | 3-year | 5-year | 1-year | 3-year | 5-year |
| Colorectal cancer | 84.7  | 56.19 | 45.01 | 48.59 |
| (n=536)          | (81.34-87.50) | (51.24-60.84) | (39.43-50.42) | (37.34-63.47) |
| Colon cancer     | 83.67 | 58.84 | 49.6  | 57.93 |
| (n=278)          | (78.75-87.54) | (52.15-64.91) | (42.13-56.61) | (42.66 – NA) |
| Rectal cancer    | 85.8  | 52.78 | 38.91 | 39.34 |
| (n=258)          | (80.85 – 89.55) | (45.24-59.76) | (30.49-47.23) | (33.44-49.44) |

CIs, confidence interval; NA, not applicable

## Table 3. Univariate Analysis of Baseline Characteristics and Survival of Colorectal Cancer Patients

| Factors                          | Total | Death | Events/ 1000 months | Median OS (months) | Crude HR (95%CI) | p-value* |
|----------------------------------|-------|-------|---------------------|-------------------|------------------|----------|
| Age groups (years)               |       |       |                     |                   |                  | <0.001   |
| < 50                             | 112   | 48    | 12.68               | 56.56             | ref              |          |
| 50 - 59                          | 103   | 33    | 10.65               | 68.56             | 0.81 (0.52-1.26) |          |
| 60 - 69                          | 124   | 39    | 9.90                | 68.85             | 0.78 (0.51-1.19) |          |
| 70 - 79                          | 109   | 61    | 18.51               | 34.39             | 1.43 (0.98-2.09) |          |
| ≥ 80                             | 88    | 49    | 20.5                | 25.84             | 1.57 (1.05-2.34) |          |
| Gender                           |       |       |                     |                   |                  | 0.563    |
| Female                           | 241   | 108   | 14.53               | 49.21             | ref              |          |
| Male                             | 295   | 122   | 13.45               | 47.73             | 0.93 (0.72-1.20) |          |
| Comorbidities                    | 0.851 |       |                     |                   |                  |          |
| No                               | 345   | 154   | 14.06               | 47.74             | ref              |          |
| Yes                              | 191   | 79    | 13.7                | 55.25             | 0.97 (0.74-1.28) |          |
| Tumor sites                      | 0.313 |       |                     |                   |                  |          |
| Colon                            | 278   | 117   | 12.86               | 57.93             | ref              |          |
| Rectum                           | 258   | 113   | 15.25               | 37.87             | 1.14 (0.88-1.48) |          |
| Residence                        | 0.98  |       |                     |                   |                  |          |
| Urban                            | 341   | 144   | 13.87               | 49.21             | ref              |          |
| Rural/ mountainous               | 195   | 86    | 13.97               | 47.74             | 1.003 (0.77-1.31) |          |
| TNM Stages                       | <0.001|       |                     |                   |                  |          |
| Stage I                          | 32    | 4     | 3.20                | -                 | ref              |          |
| Stage II                         | 111   | 26    | 7.50                | -                 | 2.25(0.79-6.46)  |          |
| Stage III                        | 114   | 41    | 11.90               | 49.21             | 3.60 (1.29-10.07)|          |
| Stage IV                         | 70    | 53    | 39.10               | 16.95             | 11.88 (4.29-32.89)|          |
| Unknown stage                    | 209   | 109   | 15.10               | 40.23             | 4.77 (1.76-12.94)|          |
| BMI group (n=490)                | 0.002 |       |                     |                   |                  |          |
| Normal                           | 266   | 103   | 12.86               | 48.59             | ref              |          |
| Overweight                       | 52    | 11    | 6.61                | NA                | 0.53 (0.29-0.1.03) |          |
| Obesity                          | 41    | 21    | 20.28               | 31.44             | 1.53 (0.96-2.45) |          |
| Underweight                      | 131   | 73    | 18.30               | 34.79             | 1.48 (1.10-2.00) |          |
| Preoperative CEA level (n=404)   | 0.001 |       |                     |                   |                  |          |
| Non elevated                     | 197   | 71    | 9.60                | 80.95             | ref              |          |
| Elevated                        | 207   | 101   | 16.71               | 34.39             | 1.70 (1.25-2.31) |          |
| Treatment modalities             |       |       |                     |                   |                  |          |
| SR only                          | 191   | 72    | 10.70               | 83.93             | ref              | <0.001   |
| SR +CT or RT                     | 195   | 84    | 13.96               | 49.44             | 1.24 (0.90-1.70) |          |
| SR + CT + RT                     | 70    | 28    | 14.33               | 42.66             | 1.20 (0.78-1.87) |          |
| CT/ RT without SR                | 36    | 18    | 24.43               | 31.15             | 2.07 (1.13-3.48) |          |
| Not at all                       | 44    | 28    | 26.13               | 21.31             | 2.34(1.51-3.62)  |          |

HR, hazard ratio; ref, reference group; NA, not applicable; SR, surgical resection; CT, chemotherapy; RT, radiotherapy; *Log-rank test.
In the literature, the survival rate can reflect the quality of healthcare services, such as an accurate diagnosis, effective management, and treatment of cancer patients (Coleman et al., 2011). In this study, the median follow-up duration was 24 months, from 7 days to 90 months. In general, half of the CRC patients survived after 48 months (median OS, 48.59; 95%CI, 37.34–63.47), which was comparable to the median OS of Malaysian citizens (42.00 months, 95%CI: 35.42–48.58) (Magaji et al., 2017), but lower than that in Brunei (57.0 months, 95% CI: 42.4–79.9) (Leong et al., 2020).

In terms of prognostic factors of the mortality rate of CRC patients, the disease stage is consistently considered an independent risk factor of mortality in the literature (Maringe et al., 2013; Wild CP et al., 2020). In our results, cancer patients in an advanced stage (stage III + IV, 34.33%) had a higher mortality rate than those in the early stage (26.68%) (Table 1). Although a high number of patients were found without a disease stage (39%), this rate is comparable with other studies in neighboring countries (Magaji et al., 2017; Phimha et al., 2019). In this study, the disease stage was observed to be statistically significant in bivariate and multivariate analyses. The 5-year OS of patients with an early diagnosis was 70.6% (95%CI: 58.6–81.0) compared to 31.9% (95%CI: 22.6–41.6) in the advanced stage. In addition, CRC patients with an advanced stage had a 3.04 times increased risk of mortality (HR, 3.04 [1.79–5.18]) (Table 4), which are similar to those of previous studies (Yuan et al., 2013; Magaji et al., 2017; Phimha et al., 2019).

| Factors                  | Adjusted HR* (95% CI) | p     | Test proportional assumption |
|--------------------------|-----------------------|-------|-----------------------------|
| Age groups (years)       |                       |       |                             |
| <50                      | ref                   |       |                             |
| 50-59                    | 0.99 (0.55-1.79)      | 0.969 | 0.001                       |
| 60-69                    | 0.47 (0.24-0.91)      | 0.025 | 0.168                       |
| ≥70                      | 1.23 (0.68-2.23)      | 0.484 | 0.037                       |
| Stage groups             |                       |       |                             |
| I + II (early stage)     | ref                   |       |                             |
| III+IV (advanced stage)  | 3.04 (1.79-5.18)      | <0.001| 0.011                       |
| BMI groups               |                       |       |                             |
| Normal                   | ref                   |       |                             |
| Overweight               | 1.04 (0.43-2.49)      | 0.953 | 0.104                       |
| Obesity                  | 1.48 (0.65-3.32)      | 0.355 | 0.011                       |
| Underweight              | 1.65 (1.03-2.65)      | 0.037 | 0.016                       |
| Preoperative CEA level   |                       |       |                             |
| Non elevated             | ref                   |       |                             |
| Elevated                 | 1.63 (1.03 – 2.59)    | 0.038 | 0.094                       |

*) Adjusted for tumor sites, treatment modalities, sex, and comorbidities. Harrell's C= 0.7102, global test =0.2839. Multivariate analysis was performed in 232 samples.

![Figure 1. The Eligible Participants](image)
The relationship between age at diagnosis and outcome of CRC patients has been consistently reported in many previous studies (Van et al., 2015; Sharakha et al., 2017; Gabriel et al., 2018; Kittrongsiri et al., 2020; Leong et al., 2020). Currently, the aging population trend is occurring worldwide, including Vietnam. In our sample, approximately 60% of patients were older (≥60 years), and a lower median OS was reported in the older group, particularly those aged ≥70 years. Older patients had an obviously increased mortality risk; however, a slightly higher rate of poor outcome was also observed in younger patients (Table 3). Several studies have shown that young patients with CRC are diagnosed late and show poor pathology (Chou et al., 2011; Berut et al., 2013). In this study, we found that the middle-aged group (aged 60–69 years) had a lower risk of mortality than the younger age group (aged <50 years) (HR, 0.47; 95%CI, 0.24–0.91). These results are similar to those of other studies in China: the 5-year survival differed between age groups and younger patients had a slightly lower OS than those aged 60–74 years (Yuan et al., 2013).

Our findings showed that half of the cases had a normal weight (18.5 to <23.0 kg/m²) at baseline. The OS was significantly different between the BMI groups (Table 3), and the median OS was 48.59, 31.44, and 34.79 for the normal, obese, and underweight groups, respectively. In the multivariate analysis, a poor effect of BMI was statistically significantly different on the OS of the underweight group (HR, 1.65; 95%CI, 1.03–2.65). In our cohort, an underweight status was commonly reported at diagnosis (24.4%). To date, the effects of BMI on the survival rate of CRC patients are still inconsistent (Wang et al., 2017). According to a recently published article, the authors found that BMI at diagnosis was associated with all-cause and CRC-specific mortalities in a nonlinear fashion. Underweight patients had a higher mortality risk (HR, 2.65; 95%CI, 1.63–4.31) (Kroenke et al., 2016). Our findings maintained the relationship between the OS and BMI groups following a U-shaped pattern (Wang et al., 2017). This result was similar to the findings of a systematic review; underweight patients had an increased risk of all-cause mortality (RR, 1.43; 95%CI, 1.26–1.62), and overweight patients did not have any significant risk of any outcomes (Doleman et al., 2016).

Preoperative serum CEA, a glycoprotein of bullous pemphigoid antigen ~180 kDa, is frequently expressed in colorectal tumors (Hayat, 2009). In our samples, more than 75% of patients were evaluated for CEA level upon admission, and more than half of them had elevated serum CEA levels (>5 ng/mL) (Table 1). CRC patients with elevated preoperative CEA levels had a higher risk of mortality than those with nonelevated CEA levels (HRadj, 1.63; 95%CI, 1.03–2.59). The role of CEA level in our findings are consistent with the findings of previous studies. Higher CEA levels are a significant prognostic factor for OS and disease-free survival in Vietnam (Nguyen et al., 2019). In a tertiary hospital cohort in Malaysia, the preoperative CEA level was significantly associated with the 5-year survival rate of patients with CRC (Magaji et al., 2017). Similarly, the 5-year survival of Chinese patients differed significantly with serum CEA levels (Yuan et al., 2013).

In conclusion, our findings indicate that the OS of Vietnamese patients with CRC was lower than that in Asian countries and developed nations. Less than 50% of patients survive 5-year after a CRC diagnosis. The disease stage is a critical prognostic marker of survival rate, and late-stage diagnosis remains high in Vietnamese patients. Therefore, we recommend that priority strategies should be encouraged for early diagnosis through active examination of and screening programs for the high-risk group. Other individual factors that contribute to the poor OS of CRC patients, such as the young age, underweight, and elevated preoperative CEA level, should be evaluated and managed.

Author Contribution Statement

DLD, TVT, and PS contributed to the development of the study design and conceptual framework of this research. TVT and PS co-supervised and revised the manuscript. DLD prepared the draft manuscript, collected data, analyzed, and interpreted the results. All authors have read and approved the final manuscript.

Acknowledgments

We would like to thank the staffs of Hue Central Hospital, Health Department, District Medical Centers and Community Health Centers in Thua Thien Hue Province, Vietnam, for their support during data collection. We sincerely thank the KKU scholarship and Faculty of Public Health, Khon Kaen University, Thailand, for the financial and teaching supports.

Funding statement

The study was funded by the Institute for Community Health Research, University of Medicine and Pharmacy, Hue University, Vietnam.

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical consideration

The study was approved by the Ethical Committee of Hue University of Medicine and Pharmacy, Vietnam (no. H2019/430), and Khon Kaen University Ethics Committee for Human Research, Thailand (no.HE632177).

Availability of data

This study is part of the approved student PhD thesis in Epidemiology and Biostatistics Program, Khon Kaen University, Thailand and data is available upon request.

References

Aguiar JS, Oliveira MM, Silva D, et al (2020). Survival of patients with colorectal cancer in a cancer center. Arq Gastroenterol, 57, 172-7.
Agymang-Yeboah F, Yorke J, Obirikorang C, et al (2012). Colorectal cancer survival rates in Ghana: A retrospective hospital-based study. PLoS One, 13, e0209307.
Arnold M, Sierra MS, Laversanne M, et al (2017). Global patterns and trends in colorectal cancer incidence and mortality. *Gut*, **66**, 683-91.

Berut M, Mik M, Keždiž-Berut R, et al (2013). Colorectal cancer in young and elderly patients. *Pol Przegl Chir*, **85**, 446-51.

Chou CL, Chang SC, Lin TC, et al (2011). Differences in clinicopathological characteristics of colorectal cancer between younger and elderly patients: an analysis of 322 patients from a single institution. *Am J Surg*, **202**, 574-82.

Coleman MP, Forman D, Bryant H, et al (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet*, **377**, 127-38.

Doleman B, Mills KT, Lim S, et al (2016). Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis. *Tech Coloproctol*, **20**, 517-35.

Ferlay J, Laversanne M, Ervik M, et al (2020). Global Cancer Observatory: Cancer Tomorrow [Online]. Lyon, France: International Agency for Research on Cancer. Available: https://gco.iarc.fr/tomorrow [Accessed 18 December 2020].

Hoang VM, Tran VT, Shu XO (2019). Scientific Evidence Manual, 7th Edition France, Springer.

Kittrongsiri K, Wanichsuwan W, Prechawittayakul P, et al (2020). General Statistics Office of Vietnam (2020). Completed results of the 2019 Viet Nam population and housing census, Ha Noi, Vietnam, Statistical Publishing House.

Hayat MA (2009). Methods of colorectal cancer diagnosis, therapy and treatment, Springer.

Hoang VM, Tran VT, Shu XO (2019). Scientific Evidence for Cancer Control in Vietnam. *Cancer Control*, **26**, 1073274819866450.

Hong TT, Phuong Hoa N, Walker SM, et al (2018). Completeness and reliability of mortality data in Viet Nam: Implications for the national routine health management information system. *PLoS One*, **13**, e0190755.

Hue Central Hospital (2020). General Introduction [Online]. Hue, Vietnam. Available: http://bvtwhue.com.vn/Home/ Index/?lang=en [Accessed 15 December 2020].

Joachim C, Macni J, Drame M, et al (2019). Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry. *Medicine (Baltimore)*, **98**, e16941.

Kittromnirsi K, Wanichsuwan W, Prechawittayakul P, et al (2020). Survival analysis of colorectal cancer patients in a Thai hospital-based cancer registry. *Expert Rev Gastroenterol Hepatol*, **14**, 291-300

Kroonenke CH, Neugebauer R, Meyerhardt J, et al (2016). Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. *JAMA Oncol*, **2**, 1137-45.

Leong E, Ong SK, Madli F, et al (2020). Survival rates and associated factors of colorectal cancer patients in Brunei Darussalam. *Asian Pac J Cancer Prev*, **21**, 259-65.

Li X, Zhou Y, Luo Z, et al (2019). The impact of screening on the survival of colorectal cancer in Shanghai, China: a population based study. *BMC Public Health*, **19**, 1016.

Magaji BA, Moy FM, Roslani AC, et al (2017). Survival rates and predictors of survival among colorectal cancer patients in a Malaysian tertiary hospital. *BMC Cancer*, **17**, 339.

Maringe C, Walters S, Rachet B, et al (2013). Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000–2007. *Acta Oncologica*, **52**, 919-32.

Moghimi-Dekhordi B, Safaee A (2012). An overview of colorectal cancer survival rates and prognosis in Asia. *World J Gastrointest Oncol*, **4**, 71-5.

Nguyen TQ, Bui TO, Tran PT, et al (2019). Modified Folfox6 as adjuvant chemotherapy in Vietnamese patients with colorectal cancer. *Cancer Control*, **26**, 1073274819864111.

Pham T, Bui L, Kim G, et al (2019). Cancers in Vietnam-Burden and Control Efforts: A Narrative Scoping Review. *Cancer Control*, **26**, 1073274820966414.

Shin HR, Carlos MC, Varghese C (2012). Cancer control in the Asia Pacific region: current status and concerns. *Jpn J Clin Oncol*, **42**, 867-81.

Siegel RL, Miller KD, Fedewa SA, et al (2017). Colorectal cancer statistics, 2017. *CA Cancer J Clin*, **67**, 177-93.

Stephen E, David R, Carolyn C, et al (2010). AJCC Cancer Staging Manual, 7th Edition France, Springer.

Takamakoshi A, Nakamura K, Ukawa S, et al (2017). Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project. *J Epidemiol*, **27**, S36-S42.

Tran VT, Pham TA, Dao VT, et al. 2016. Cancer control in Vietnam: where are we? [Online]. Cancer control. Available: http://www.cancercontrol.info/ce2016/cancer-control-vietnam-where-we-are/ [Accessed January 15 2019].

United Nations 2020. World Economic Situation and Prospects 2020, United Nations.

Van EEE, Bakker SD, Van BA, et al (2015). Impact of age and comorbidity on survival in colorectal cancer. *J Gastrointest Oncol*, **6**, 605-12.

Wang N, Khankari NK, Cai H, et al (2017). Prediagnosis body mass index and waist-hip circumference ratio in association with colorectal cancer survival. *Int J Cancer*, **140**, 292-301.

World Health Organization (2000). The Asia-Pacific perspective: redefining obesity and its treatment, Sydney, Australia.

Yuan Y, Li MD, Hu HG, et al (2013). Prognostic and survival analysis of 837 Chinese colorectal cancer patients. *World J Gastroenterol*, **19**, 2650-9.